Cysview

Communication
Toolkit

This Communication Toolkit is designed to help you and your institution raise awareness about bladder cancer and the availability of Blue Light Cystoscopy (BLC®) with Cysview at your location.

Cysview is the only FDA-approved agent for use in BLC. It is an optical imaging agent indicated for the detection of non-muscle invasive bladder cancer, including carcinoma in situ, in patients:

Suspected or known to have lesion(s) based on a prior cystoscopy or
Undergoing surveillance cystoscopy for carcinoma of the bladder.

Provided in this Communication Toolkit are educational resources to help with:

Introduction to this educational resource

This Communication Toolkit is designed to help you publicize the availability of BLC with Cysview to a variety of audiences who will find this news relevant – and even life-changing.

While the information in this Communication Toolkit can be used by anyone, it is organized by different user types to create greater relevance for each user.

Feel free to explore all the resources available or simply jump to the section within the Communication Toolkit that best matches your situation. There is information for:

Available templates are written from two different perspectives, when appropriate:

You are invited to copy and paste the templates provided in this Communication Toolkit and make them your own on facility stationery; or you can simply use these suggestions as a guide to create your own unique marketing program. We hope you find this Communication Toolkit useful in some way.

Important safety information about Cysview® (hexaminolevulinate HCI)

Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.
Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain.

Product indication for Cysview® (hexaminolevulinate HCl)

Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder.

Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLC®) as an adjunct to White Light Cystoscopy.

Important Risk & Safety Information

Limitations of use
Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.

Warnings and precautions
Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain.

Contraindications
Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False-positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy, and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed.

Use in specific populations
Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition.

Use of the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system
Cysview is approved for use with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components.

Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.

BLC® and Cysview® are registered
trademarks of Photocure ASA

The information on this website is intended for U.S audiences only.
Residents of Canada, please visit Cysview.ca.